

Novotech inks MoU with Wonju Severance Christian Hospital to drive clinical research excellence in Korea

19 February 2025 | News

To foster innovation and support Korea's aspiration to lead the globalisation of its medical industry



Novotech, a global full-service clinical Contract Research Organisation (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics at every phase, has signed a Memorandum of Understanding (MoU) with Wonju Severance Christian Hospital.

The partnership between Wonju Severance Christian Hospital, located in Gangwon province of South Korea and Novotech marks the beginning of a new strategic collaboration focused on enhancing clinical research and medical innovation.

The partnership brings together Novotech's global expertise in clinical trial management and Wonju Severance Christian Hospital's outstanding research capabilities. The two organisations aim to enhance the quality of clinical trials and contributing to the development of cutting-edge therapeutics and improving patient care in the region.

Through the strategic alliance, Novotech and Wonju Severance Christian Hospital aim to set new leverage their combined expertise to set new standards in clinical trials and medical services. The partnership will foster innovation and support Korea's aspiration to lead the globalization of its medical industry.